0000000000791170

AUTHOR

Cristina Pascual Izquierdo

showing 2 related works from this author

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

2020

INTRODUCTION Coronavirus disease 2019 (COVID-19) caused by SARS-CoV2 virus is thought to be more severe in patients with prior hematological diseases. There is evidence suggesting that hematological patients are particularly vulnerable and have a higher risk of developing severe events, with higher mortality rate than general population. However, the available data are limited, and prognostic factors at admission still remain unclear. With this background, our aims were to analyze the impact of hematological diseases and their therapy on the COVID-19 severity and to identify clinical and biological risk factors to predict the outcome in these patients. METHODS We carried out a multicenter …

medicine.medical_specialtyeducation.field_of_studybusiness.industryMortality rateImmunologyPopulation203.Lymphocytes Lymphocyte Activation and Immunodeficiency including HIV and Other InfectionsRetrospective cohort studyCell BiologyHematologyDiseasemedicine.diseaseBiochemistryComorbidityMulticenter studyInternal medicineIntensive caremedicineIn patienteducationbusinessBlood
researchProduct

Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura.

2021

Introduction Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury. TTP pathophysiology is based on a severe ADAMTS13 deficiency, and is a medical emergency with fatal outcome if appropriate treatment is not initiated promptly. Areas covered Authors will review the best options currently available to minimize mortality, prevent relapses, and obtain the best clinical response in patients with immune TTP (iTTP). Available bibliography about iTTP treatment has been searched in Library's MEDLINE/PubMed database from January 1990 until April 2021. Expert opinion The general…

medicine.medical_specialtyPurpura Thrombocytopenic IdiopathicThrombotic microangiopathyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industrymedicine.medical_treatmentThrombotic thrombocytopenic purpuraADAMTS13 ProteinHematologyMicroangiopathic hemolytic anemiaDiseasemedicine.diseaseADAMTS13Targeted therapyPharmaceutical Preparationshemic and lymphatic diseasesmedicineHumansRituximabCaplacizumabIntensive care medicinebusinessRituximabmedicine.drugExpert review of hematology
researchProduct